Nov. 18, 2024 — Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to treat people with atrial fibrillation (AFib) who are at an increased risk of stroke. The new five-year findings demonstrate that Abbott's Amplatzer Amulet helps more patients avoid long-term use of blood-thinning medication compared to the Watchman device.

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L).

Nov. 16, 2024  Anthos Therapeutics, Inc.recently presented new data at the American Heart Association (AHA) Scientific Sessions from its AZALEA-TIMI 71 study that demonstrated the novel factor XI inhibitor abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, as compared to rivaroxaban.

The deadline for early bird discounts for HIMSS25 is rapidly approaching.

Register by December 15 to save up to $500 on your pass for the HIMSS Global Health Conference & Exhibition.

HIMSS Global Health Conference & Exhibition will take place in Las Vegas, March 3-6, 2025.

For more information, please visit www.himssconference.com

 

Nov. 13, 2024 – A recent study has demonstrated the value of the single-exposure dual-energy X-ray detector in advancing cardiovascular risk assessment.

Nov. 4, 2024 — Royal Philips recently announced enrollment of the first patient in the U.S. THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter that integrates two critical PAD treatments into a single device. Procedures that previously required the use of two different devices can now be performed in a single procedure using a single device, simplifying workflows and procedures and potentially reducing the risk and improving outcomes for patients who might otherwise face multiple complex interventions. 

Medtronic recently announced results from two studies evaluating the utility of atherectomy for peripheral endovascular interventions. Results from both analyses were released at the Vascular InterVentional Advances (VIVA) 2024 conference in Las Vegas.

Nov. 1, 2024 — Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co. recently announced U.S. Centers for Medicare & Medicaid Services (CMS) have granted the company’s Paradise Ultrasound Renal Denervation system a Transitional Pass-through (TPT) payment. The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years.

Nov, 4, 2024 – R3 Vascular Inc. has announced that the U.S. Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval to initiate its ELITE-BTK pivotal trial of its next generation drug eluting bioresorbable scaffold, MAGNITUDE, for below-the-knee (BTK) PAD. 

Oct. 28, 2024 — Cardiawave SA, developer of Valvosoft Non-Invasive Ultrasound Therapy (NIUT) device for treating severe symptomatic calcific aortic stenosis (CAS),  announced that the device met the primary endpoint in its pivotal study and improved or stabilized heart failure symptoms for 80.5 percent of patients, substantially improving hemodynamics and patient quality of life six months after treatment.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now